Skip to main content
Premium Trial:

Request an Annual Quote

Hmm, That Sounds Interesting...

At In the Pipeline, Derek Lowe asks in which fields people would consider starting a small drug company. He writes that oncology would have been a good choice a decade ago and that going into cardiovascular disease and metabolic disorders doesn’t make much sense, unless you've been sitting on a golden egg. Alzheimer's disease, he says, is an under-served market, adding that "it's unserved for a lot of damned good reasons. The same goes for a number of other CNS indications. This whole area is a tightrope of risk and reward. Both are huge." In the comments, people offer suggestions from veterinary medicine to non-hormonal birth control pills to, well, snake oil. Lowe says he's not starting a company, but says that perhaps someone who is might see a good idea.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.